P oint mutations are a frequent cause of genetic diseases, with approximately 50% of disease-associated point mutations being G:C>A:T 1 . CRISPR genome editing, which consists of generating double-stranded DNA breaks followed by nonhomologous end-joining (NHEJ) or homology-directed repair (HDR), has been applied to many organisms 2,3 . However, major caveats of correcting point mutations through CRISPR genome editing include system efficiency, the introduction of double-stranded DNA breaks and the need to provide a DNA-repair template. A new generation of genome-editing tools, the base editing system, enables precise base changes 4, 5 , does not induce a high level of double-stranded DNA breaks and does not require HDR donors for gene repair 4, 5 .
To date, two classes of base editors have been developed 1, 6 . Cytosine base editors, which include cytosine deaminases, Cas9 nickases and the uracil glycosylase inhibitor, introduce C•G to T•A base changes 6 and have been used to successfully introduce a stop codon or correct T•A to C•G mutations in prokaryotes, fungi, plants, insects, amphibians, fish and mammals 5, [7] [8] [9] [10] [11] . ABEs comprise an evolved Escherichia coli TadA (EcTadA*, a tRNA adenosine deaminase evolved to accept DNA substrate) and Cas9 nickase and mediate A•T to G•C substitutions 1 . Local delivery of ABEs by intramuscular injection of a trans-splicing adeno-associated virus was recently reported 12 ; however, systemic delivery of ABEs for correction of liver disease in adult animals has not been investigated.
To explore the therapeutic potential of ABEs in the liver of adult animals, we chose a mouse model of hereditary tyrosinaemia type I (HTI), a fatal genetic disease. HTI is caused by loss of function of fumarylacetoacetate hydrolase (FAH), a key enzyme of the tyrosine catabolic pathway 13, 14 . FAH deficiency leads to accumulation of toxic metabolic intermediates, causing apoptosis of mutant hepatocytes and severe liver damage. The Fah mut/mut mouse model 14, 15 has a homozygous G•C to A•T point mutation in the last nucleotide of exon 8, resulting in exon skipping and loss of FAH. 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) 14 is an inhibitor of the tyrosine catabolic pathway upstream of FAH. To be kept alive, Fah mut/mut mice need to be treated with NTBC-supplemented water to prevent the build-up of toxins and liver damage 14 .
We and others recently reported that CRISPR can correct this mutation in Fah through HDR [16] [17] [18] or allelic exchange 19 . Following correction by CRISPR, liver cells that express the FAH enzyme, through their selective advantage, expand and repopulate the liver 14 .
Thus, this mouse model is particularly suitable for testing ABEs 13, 15 .
Results
Using adenine base editing to correct a Fah point mutation. The adenine base-editing window occupies positions ~4-9 with the first, 5′ nucleotide (nt) of the candidate sgRNA counted as position 1 1 . To edit the mutation in Fah using ABEs, we selected a previously validated Fah sgRNA 20 (Fig. 1a ). The disease-associated point mutation is located at position 9 (A9). This sgRNA has the only sgRNA position that contains the necessary 'NGG' protospacer-adjacent motif and targets the mutation ' A' within the adenine base-editing window. Notably, ABE-mediated editing at position A6 will change a serine codon into alanine (S235A), but this editing will not restore splicing. Initially, we tested different doses of two ABE enzymes with different base-editing windows 1 In contrast to traditional CRISPR-Cas9 homology-directed repair, base editing can correct point mutations without supplying a DNA-repair template. Here we show in a mouse model of tyrosinaemia that hydrodynamic tail-vein injection of plasmid DNA encoding the adenine base editor (ABE) and a single-guide RNA (sgRNA) can correct an A>G splice-site mutation. ABE treatment partially restored splicing, generated fumarylacetoacetate hydrolase (FAH)-positive hepatocytes in the liver, and rescued weight loss in mice. We also generated FAH + hepatocytes in the liver via lipid-nanoparticle-mediated delivery of a chemically modified sgRNA and an mRNA of a codon-optimized base editor that displayed higher base-editing efficiency than the standard ABEs. Our findings suggest that adenine base editing can be used for the correction of genetic diseases in adult animals. literature 1 , ABE6.3 resulted in the highest A>G base-editing efficiency at position A9 (6.9 ± 2.0%,2 µg ABE6.3, compared to an efficiency of 2.69 ± 1.14 for ABE7.10) ( Supplementary Fig. 1 ) and editing efficiency was dependent of the concentration of the ABE enzyme. We therefore chose to test ABE6.3 in mice.
Adenine base editing generates FAH + hepatocytes in the liver of adult mice. To deliver ABEs to the liver of adult mice, we performed hydrodynamic tail-vein injection 21 with ABE6.3 and our validated Fah sgRNA plasmids (ABE hereafter, Fig. 1b ). We removed NTBCsupplemented water 6 days after hydrodynamic injection to initiate HTI symptoms in Fah mut/mut mice. As shown in Fig. 1c , Fah mut/mut mice injected with control PBS or ABE6.3 alone rapidly lost 20% of their total body weight. By contrast, ABE6.3 and Fah sgRNA rescued weight loss in all five mice ( Fig.1c ).
To examine whether adenine base editing generates FAH + hepatocytes in vivo, we euthanized three of the five mice at day 32, collected the liver and stained liver sections with a FAH-specific antibody by immunohistochemistry (IHC). As shown in Fig. 1d and Supplementary Fig. 2 , adenine base editor generated widespread patches of FAH + hepatocytes in the livers of Fah mut/mut mice owing to the expansion of corrected hepatocytes 14 . Concordantly, ABEtreated mice showed improved liver histology compared to the liver damage in control Fah mut/mut mice that did not receive NTBC water ( Fig. 1d and Supplementary Fig. 3 ). Consistent with published literature 14, 15 , the rapid expansion of FAH + hepatocytes in the Fah mut/mut liver contributed to the rescue of weight loss in mice treated with ABEs 14 . These data indicate that adenine base editing rescues the disease phenotype caused by the Fah mutation in vivo.
To determine whether adenine base editing successfully corrects the HTI Fah splicing mutation in exon 8, we performed reverse transcription PCR (RT-PCR) in liver mRNA using primers that spanned exons 5 and 9. As shown in Fig. 2a , we found that the wild-type liver had a 405-bp PCR band that contained exon 8 and the Fah mut/mut liver had a 305-bp PCR band, which corresponds to the truncated form of Fah mRNA that lacks exon 8. In ABE-treated Fah mut/mut mice (after NTBC withdrawal and hepatocyte expansion), we observed both 305-and 405-bp PCR bands, indicating that exon 8 to exon 9 splicing was restored in a subset of hepatocytes. Sequencing of the 405-bp bands in ABE-treated mice confirmed the presence of the corrected 'G' at position A9 (Fig. 2b) . These data indicate that in vivo delivery of ABEs corrects the G•C to T•A mutation in a subset of liver cells and generates functional exon 8-containing Fah mRNA.
Adenine base editing partially corrects the Fah mutation in the liver. To quantify the edited alleles after NTBC withdrawal, we amplified the Fah genomic region by PCR from liver DNA (using the same mice as in Fig. 1d ) and performed amplicon deep sequencing. We observed that the A9 to G correction rate was 9.5 ± 4.0% (n = 6, Fig. 2c and Supplementary Table 1 ). Because many hepatocytes are 4N cells 20 , it is possible that A9 in one allele was converted into G in the edited 4N hepatocytes.
Because position A6 of the Fah site is within the editing window of the ABE (Fig. 1a ), we also evaluated the editing efficiency at this position. We detected 1.9 ± 0.9% A6 to G editing in the liver (Fig. 2c ). Compared to in vitro editing in MEFs ( Supplementary Fig. 1 ), the in vivo detection of relatively lower A6 to G editing is probably because of repopulation of A9-to-G-edited healthy cells in the liver rather than to an in vivo preference for A9 editing. The rate of both A6 to G and A9 to G editing ( Fig. 2c ) is low (around 0.1%). Editing position A6 to G will change a serine codon into alanine (S235A) in the FAH enzyme. Because S235 is near the active site of the FAH enzyme 22 , the A6G/A9G allele may compromise enzyme activity and impede functional rescue of edited hepatocytes.
We also measured the rate of insertions and deletions (indels) by deep sequencing. The detected indel rate was very low (0.05% in ABE and 0.03% in control) even after expansion of the edited hepatocytes ( Fig. 2c and Supplementary Table 2 ). These data suggest that ABE can directly correct the mutation in Fah without causing a high level of indel mutations. The two remaining ABE-treated mice were viable with a normal body weight at 106 days without NTBC treatment ( Fig. 2d and Supplementary Fig. 4 ), demonstrating the longterm viability and functionality of ABE-treated hepatocytes.
Analysis of the off-target activity of ABE.
To globally identify the off-target activity of ABE, we performed genome-wide Guide-seq 23 in vitro followed by in vivo deep sequencing at selected off-target sites in mouse livers. First, we evaluated off-target activity in vitro using mouse Hepa1-6 cells stably expressing Cas9 and transfected with sgFah and Guide-seq oligomers 16 . Using the standard Guide-seq protocol, we detected only the Fah target site and one off-target site (defined as Guide-seq off-target site 1, or GOT1) (Supplementary Data 1). These data suggest that the Fah sgRNA used in this study is not associated with a large number of strong off-target sites. Next, we performed targeted deep sequencing in vivo in both control and ABE-treated livers. We did not detect increased A•T to G•C editing at GOT1 in ABE-treated livers compared to controls (n = 4 mice, P > 0.05) ( Supplementary Fig. 5 ).
To expand our analysis, we sequenced four predicted top-ranking off-target sites in ABE-treated livers (n = 6) and did not detect A•T to G•C editing above the background level in a control liver (all rates were less than 0.1%) ( Supplementary Fig. 6 ). Because the overall on-target ABE efficiency in our in vivo study is relatively low, detecting off-target effects is difficult. Future work is needed to further study potential off-target editing of ABE 24, 25 . A codon-optimized RA6.3 improves ABE activity. New reports have indicated that the efficiency of base editing can be improved with codon optimization of the Cas9 nickase and inclusion of an N-terminal nuclear localization sequence 26, 27 . Optimized cytosine base editors and ABE7.10 have been reported 26, 27 ; however, optimization of ABE6.3 has not been performed. To test whether we could improve Fah base editing in our system, we cloned an optimized Cas9 nickase 26 into ABE6.3 (Fig. 3a) (called reassembled ABE6.3 or RA6.3). When transiently transfected in cells, our optimized base editor, RA6.3, showed substantially higher expression than ABE6.3 ( Supplementary Fig. 7) . To validate the efficiency of our optimized base editor, we transfected HEK293T cells with a selected sgRNA sequence with multiple ' A' sites 1 to evaluate A•T to G•C substitution by position (Fig. 3b) . Deep sequencing showed an increase of base-editing efficiency at all adenine positions (including A9) with use of our codon-optimized ABE RA6.3 (Fig. 3b) .
To further confirm that RA6.3 improves editing efficiency, we compared the A-to-G conversion efficiency of ABE6.3 and RA6.3 at two other genomic sites in HEK293T cells (Fig. 4a,b) . Our optimized RA6.3 increased A-to-G conversion rate at all the editable ' A' sites within the editing window by an average of 2.1 ± 0.9-fold (site 1) and 4.8 ± 1.8-fold (site 2). Next, we compared the editing efficiency of HDR (100-nt single-stranded donor DNA) 1 , ABE6.3 and RA6.3 at two genomic sites in HEK293T cells (Fig. 4c,d) . Compared with HDR using short homologous arms (site 1:1.7 ± 1.1%; site 2: 1.8 ± 0.8%), ABE6.3 mediated substantially higher A•T to G•C conversion rates at the targeted sites (site 1: 30 ± 6.3%; site 2: 7.3 ± 1.6%), whereas RA6.3 further increased base-editing efficiency (site 1: 61 ± 6.3%; site 2: 34 ± 3.2%). These results confirm that the optimized ABE6.3 variant improves editing efficiency in cultured cells.
To compare RA6.3 and ABE6.3 in vivo, we measured the Fah editing efficiency following hydrodynamic injection of plasmids (Fig. 5a ). IHC staining showed that RA6.3 generated more FAH + hepatocytes than ABE6.3 (Fig. 5b,c , P < 0.05). This result was confirmed by deep sequencing of the Fah target site ( Supplementary  Fig. 8a ). In addition, RA6.3 increased base editing at a second mouse genomic site in vivo compared to ABE6.3 ( Supplementary Fig. 8b ). Our combined in vitro and in vivo results indicate that RA6.3 is a robust base editor in mammalian cells and in the mouse liver.
Lipid nanoparticle-mediated delivery of ABE mRNA and sgRNA in vivo. Finally, we used lipid nanoparticle (LNP)-mediated delivery 28 through tail-vein injection to deliver our optimized RA6.3 mRNA with chemically modified single-guide RNA to the liver of adult mice ( Supplementary Fig. 9a ). To measure initial ABE efficiency, we kept the mice on NTBC water after intravenous injection to prevent hepatocyte proliferation. As shown in Supplementary  Fig. 9b , IHC images of the liver of Fah mut/mut mice injected with control PBS did not show any edited hepatocytes. By contrast, RA6.3 mRNA and Fah sgRNA showed 0.44% ± 0.28% edited hepatocytes ( Supplementary Fig. 9c ). The data suggest that non-viral delivery of ABEs is possible in the adult mouse liver and indicate the need to improve ABE mRNA stability and delivery vehicles.
Discussion
In summary, our results demonstrate that transient delivery of ABE6.3 and sgRNA by non-viral hydrodynamic injection is sufficient to generate FAH + hepatocytes and rescue the phenotypic weight loss of Fah-mutant mice. We codon-optimized ABE6.3 and showed that in vivo delivery of ABEs was able to correct the mutation in Fah in vivo without inducing high level of indels. The relatively low rate of indel formation is one notable advantage of ABE-mediated gene correction compared to Cas9-mediated HDR. Although we show phenotypic rescue in our Fah mut/mut mice, the in vivo ABE efficacy in our proof-of-concept study may not suffice to treat other genetic disorders that require higher levels of correction and that do not selectively proliferate corrected cells. Thus, further improvement of ABEs and delivery methods will continue to expand the utility of these tools.
As an initial delivery vehicle, our study also showed that nonviral LNP delivery of ABE mRNA and sgRNA generates FAH + hepatocytes in vivo, albeit with low efficiency. Because ABE mRNA is longer than Cas9 mRNA (5.2 kb compared to 4.1 kb, respectively), it is possible that the delivery or translation of ABE mRNA is less efficient than Cas9 mRNA. Methods to improve delivery and to enhance mRNA stability and/or translation will be required to broaden the therapeutic application of ABEs. This study demonstrates the potential application of adenine base editing to correct disease genes with G•C to T•A point mutations in adult mammalian models.
Methods
Construction of CRISPR vectors. The sgRNA vector (U6_sgRNA_EFS_GFP, Addgene 65656) expressing sgRNA 29 was digested with BsmBI. sgRNA oligomers were annealed, phosphorylated by T4 PNK and ligated with a linearized vector. RA6.3 vectors were cloned by Gibson assemble.
Mouse experiments. All mice study protocols were approved by the UMass IACUC. Fah mut/mut mice 14 were kept on 10 mg l −1 NTBC water. Mice with more than 20% weight loss were humanely euthanized according to guidelines. Vectors for hydrodynamic tail-vein injection were prepared using the EndoFreeMaxi kit (Qiagen). For hydrodynamic liver injection, plasmids suspended in 2 ml saline were injected via the tail vein in 5-7 s into 8-10-week-old Fah mut/mut mice. The plasmid doses were: Figs. 1, 2: 30 μg ABE plasmid and 60 μg sgFah plasmid; Fig. 5 and Supplementary Fig. 8a : 30 μg ABE plasmid (or 30 μg RA6.3) and 30 μg sgFah plasmid; Supplementary Fig. 8b : 30 μg ABE plasmid (or 30 μg RA6.3) and 15 μg sgAbc plasmid. The ABE RA6.3 mRNA was synthesized by TRILINK and the endmodified sgRNA was synthesized by Axolabs. The LNP formulation and treatment protocols were previously published 28 . In brief, 1 mg kg −1 LNP RA6.3 mRNA and 0.5 mg kg −1 LNP Fah sgRNA were injected in 8-10-week-old female Fah mut/mut mice via tail-vein injection. The mice were injected with 3-4 doses (every 3 days) and kept on NTBC water. Mice were euthanized 5 days after the last injection and organs were collected for analyses.
Immunohistochemistry. Mice were euthanized by carbon dioxide asphyxiation. Livers were fixed with 4% formalin, embedded in paraffin, sectioned at 5 μm and stained with haematoxylin and eosin for pathology. Liver sections were dewaxed, rehydrated and stained using standard IHC protocols 30 . The following antibody was used: anti-FAH (Abcam, 1:400). Representative images (of a total of more than 5 images) are shown.
Gene expression analysis and RT-PCR. RNA was purified using TRIzol (Invitrogen) and reverse-transcribed using a High-Capacity cDNA Reverse Transcription kit (Applied Biosystems). Full gel scans are shown in Supplementary Fig. 10 .
Illumina sequencing. Fah mut/mut MEFs were transformed by retroviral WZL-HRas V12 and MSCV-shp53 31 to enhance transfection efficiency. ABE plasmids were electroporated into Fah mut/mut MEFs. The genomic region containing Fah was amplified using PCR. Deep-sequencing libraries were made from approximately 1-100 ng of the PCR products. Libraries were normalized to approximately equal molar ratio and sequenced on Illumina MiSeq machines (150-bp, paired-end reads). Reads were mapped to the PCR amplicons as references using bwa with custom scripts (available from the supplementary note of a previous study 1 ). Data processing was performed according to standard Illumina sequencing analysis procedures.
Comparison of ABE6.3, RA6.3 and HDR.
HEK293T cells were seeded at a confluence of 60%. After 24 h, cells were transfected with 1 µg Cas9 or base editors, 300 ng sgRNA expression plasmid, 6 µl Lipofectamine 3000 (Thermo Fisher Scientific) and for HDR assays, 0.7 µg single-stranded donor DNA template (100 nt, PAGE-purified from IDT) 1 . Genomic DNA was collected 72 h after transcription using quickextract buffer (Epicentre). Deep sequencing was performed to measure A to G conversion. Single-stranded 100-mer oligonucleotide donor templates and primers are listed in Supplementary Tables 3 and 4 .
Guide-seq.
Deep-sequencing data from the Guide-seq experiment were analysed using the GUIDEseq v.1.10.0 Bioconductor package 32 after barcode deconvolution, adaptor removal and alignment to the mouse genome (mm10). The default settings for SpCas9 are used except that min.reads is set to 2 and min.peak. score.1strandOnly is set to 2 as described previously 33 A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Data analysis
Reads were mapped to the PCR amplicons as references using bwa with custom scripts (available in Supplementary Note 1 of ref. 1 in the paper).
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